Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.36 |
| ▸ | DHODH | Q02127 | 4/20 | 0.34 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.34 |
| ▸ | PTGES | O14684 | 4/20 | 0.33 |
| ▸ | F2R | P25116 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25085545 | 0.94 | RXFP1 (0.36) | RXFP1DHODHP2RX1F2RSMN1; SMN2 | |
| SCHEMBL25085595 | 0.90 | SMN1; SMN2 (0.38) | RXFP1DHODHPTGESSMN1; SMN2 | |
| SCHEMBL23059687 | 0.89 | DHODH (0.37) | RXFP1DHODHP2RX1PTGESF2R | |
| SCHEMBL25085575 | 0.88 | DHODH (0.36) | RXFP1DHODHP2RX1PTGESF2R | |
| SCHEMBL23059688 | 0.87 | DHODH (0.39) | RXFP1DHODHPTGESF2RBRAF | |
| SCHEMBL23059704 | 0.85 | SMN1; SMN2 (0.36) | RXFP1DHODHPTGESF2RSMN1; SMN2 | |
| SCHEMBL25085498 | 0.84 | SMN1; SMN2 (0.36) | RXFP1DHODHPTGESF2RSMN1; SMN2 | |
| SCHEMBL25085551 | 0.84 | PTGES (0.37) | RXFP1P2RX1PTGES | |
| SCHEMBL23059718 | 0.83 | RXFP1 (0.36) | RXFP1DHODHPTGESBRAFSMN1; SMN2 | |
| SCHEMBL23059627 | 0.83 | SMN1; SMN2 (0.39) | RXFP1DHODHPTGESSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230065544-A1 | ISOPHTHALAMINDE COMPOUND AND USE THEREOF | Metisa Biotechnology Co., Ltd (CN) | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230065544-A1 | ISOPHTHALAMINDE COMPOUND AND USE THEREOF | DDT, INMT, CYP2B6 | RXFP1 4724/4885DHODH 11/4885P2RX1 2468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.